These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39106345)

  • 1. Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint.
    Li Z; Geng X; Hou Y; Chen Z
    Stat Methods Med Res; 2024 Sep; 33(9):1546-1558. PubMed ID: 39106345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculation for the proportional hazards cure model.
    Wang S; Zhang J; Lu W
    Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
    Wu J
    J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy trial design with long-term survivors.
    Ding X; Wu J
    Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z; Zhang Q; Xue A; Whitmore J
    Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
    Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
    J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
    Sharma P; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.
    Quartagno M; Morris TP; Gilbert DC; Langley RE; Nankivell MG; Parmar MK; White IR
    Clin Trials; 2023 Dec; 20(6):594-602. PubMed ID: 37337728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
    Phadnis MA; Mayo MS
    Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
    Wei J; Wu J
    Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S; Chu C; Rong A
    Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NPHMC: an R-package for estimating sample size of proportional hazards mixture cure model.
    Cai C; Wang S; Lu W; Zhang J
    Comput Methods Programs Biomed; 2014; 113(1):290-300. PubMed ID: 24199658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate markers and joint models for longitudinal and survival data.
    Taylor JM; Wang Y
    Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.